Insider · CIK 0002115025
Matthew Bowen
Files at GLUE (Monte Rosa Therapeutics, Inc.). First filing Oct 6, 2026, latest Oct 6, 2026.
In brief
Matthew Bowen files SEC Form 4 as officer at GLUE (Monte Rosa Therapeutics, Inc.). Since Oct 6, 2026, Matthew Bowen has reported 0 open-market buys worth $0 and 1 open-market sell worth $137, the latest filed on Oct 6, 2026.
A track record needs three past buys with six months of prices behind them; Matthew Bowen has 0, so none is measured yet.
The newest scored trade: sold $137 of GLUE on Oct 5, 2026, filed Oct 6, 2026, scored 15 (weak). In the last 12 months: 0 buys worth $0 and 1 sell worth $137.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
GLUE: Monte Rosa Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 15Weak | GLUEsell Monte Rosa Therapeutics, Inc. | $137 13 shares | -0% | +39% from low-59% from high |
Transactions
Every row this insider has filed, 3 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 5, 2026 | GLUE Monte Rosa Therapeutics, Inc. | SOpen-market sale Common Stock | -13 | $10.56 | $137 | 25,891 | 7 d ago |
| Apr 6, 2026 | GLUE Monte Rosa Therapeutics, Inc. | AGrant or award Common Stock | +4,300 | - | - | 25,904 | Apr 7, 2026 |
| Apr 6, 2026 | GLUE Monte Rosa Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +19,500 | $0.00 | $0 | 19,500 | Apr 7, 2026 |
Questions about Matthew Bowen
Answered from the filings on this page, as of the latest one.
Is Matthew Bowen buying or selling?
In the last 12 months Matthew Bowen reported 0 open-market buys worth $0 and 1 open-market sell worth $137 on SEC Form 4; the latest was sold $137 of GLUE on Oct 5, 2026. Grants, option exercises and tax withholding are not counted.
How did Matthew Bowen's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Matthew Bowen has 0.
Where does Matthew Bowen file Form 4?
Matthew Bowen has filed Form 4 at GLUE (Monte Rosa Therapeutics, Inc.) as Principal Accounting Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.